CSCI Research Brief

Cannabidiolic Acid (CBDA) Reduces Symptoms of Rett Syndrome (RTT) Including Thermal Pain

Vigli D, Cosentino L, Pellas M, De Filippis B. Chronic Treatment with Cannabidiolic Acid (CBDA) Reduces Thermal Pain Sensitivity in Male Mice and Rescues the Hyperalgesia in a Mouse Model of Rett Syndrome. Neuroscience. 2021;453:113-123. doi:10.1016/j.neuroscience.2020.09.041

This study, published in the journal Neuroscience, evaluated the effect of cannabidiolic acid (CBDA) on RTT symptoms.

Rett syndrome (RTT) is an incurable neurological condition involving severe psychological and behavioral disorders such as loss of speech and motor skills, seizures, bruxism and screaming spells. The cause of RTT is a gene mutation, specifically the MECP2 gene. 

 Study subjects were given daily intraperitoneal injections of 0.2, 2, and 20 mg/ kg for 14 days.

Study Findings

The study suggests that non-euphoric cannabinoids from Cannabis sativa may be an innovative treatment option for RTT. The study authors concluded that systemic treatment of low dose CBDA was shown effective for treating nausea and anxiety in mice. This study also shows that systemic, low dosage treatment with CBDA resulted in anti-nociceptive effects (i.e., the blockage of pain by sensory neurons). CBDA also reduced thermal hyperalgesia in male mice, blocking the detection of a painful or injurious stimulus by sensory neurons. CBDA did not affect behavioral symptoms in study subjects with RTT. Another cannabinoid called “cannabidivarin (CBDV)” has been shown to have a therapeutic effect on behavioral symptoms in mouse models with RTT. 


These study results are favorable for the antinociceptive effects of CBDA, but more studies, including human study subjects are needed to back the claims of effectiveness and safety of CBDA to treat RTT symptoms. Study authors explain that it’s also important to learn more about the underlying mechanisms at play in the control of pain perception in RTT. Link to article:

General Disclaimer

Center for Scientific Cannabinoid Information (CSCI) has placed information, including links to other websites or content belonging to or originating from third parties, on this website as a service to the general public and for general informational and educational purposes only.  The information on this website is not intended to substitute particularized advice of specialists or qualified professionals.  No content on this website should ever be used as a substitute for direct advice from appropriate professionals or qualified specialists.  This website could include inaccuracies or typographical errors.  The materials on this website do not constitute medical advice, do not necessarily reflect the opinions of CSCI or any of its employees, agents, affiliates, or subsidiaries, and are not guaranteed to be correct, complete, or up‐to‐date.  The publications, articles, and information on this website are provided as is without warranty of any kind, either express or implied, regarding accuracy, adequacy, validity, reliability, availability, or completeness, and CSCI does not warrant, endorse, guarantee, or assume responsibility for the accuracy or reliability of any information included on this website from third-party websites linked through this website.  UNDER NO CIRCUMSTANCE SHALL CSCI HAVE ANY LIABILITY TO YOU FOR ANY LOSS OR DAMAGE OF ANY KIND INCURRED AS A RESULT OF THE USE OF THE INFORMATION CONTAINED ON THIS WEBSITE OR RELIANCE ON ANY SUCH INFORMATION PROVIDED ON THIS WEBSITE. YOUR USE OF THIS WEBSITE AND YOUR RELIANCE ON ANY INFORMATION ON THIS WEBSITE IS SOLELY AT YOUR OWN RISK.

You cannot copy content of this page